معرفی
Hassen Wollebo is an Assistant Professor at the Lewis Katz School of Medicine, Temple University, with dual appointments in the Department of Microbiology, Immunology and Inflammation and the Department of Cancer and Cellular Biology. He is a key researcher at the Center for Neurovirology and Gene Editing, where his work focuses on the molecular mechanisms of JC polyomavirus (JCV) latency and reactivation in the central nervous system.
His research interests include:
- Neurotropic viruses, particularly JCV and its role in progressive multifocal leukoencephalopathy (PML)
- CRISPR/Cas9-based gene editing as a therapeutic strategy for viral infections
- Molecular virology of viral latency and reactivation
- Glial cell biology and viral pathogenesis in the CNS
- Development of antiviral gene therapies targeting neurotropic viruses
Dr. Wollebo's recent publications reflect a strong focus on viral persistence, gene editing applications in CNS infections, and the role of JCV in neurological diseases. His work increasingly integrates CRISPR technology with virology to develop novel treatments for incurable viral diseases like PML. His research also extends to emerging neuropathological agents such as Zika virus and broader implications of viral infections in aging and oncogenesis.
Scientific contributions include:
- Developing CRISPR/Cas9 systems to disrupt JCV genome integrity
- Investigating interferon-mediated suppression of JCV
- Exploring the role of DNA repair proteins in viral transcription
- Reviewing protein quality control mechanisms in glioblastoma
- Contributing to understanding neurotropic viruses as drivers of aging
Dr. Wollebo holds a PhD from Humboldt University, Berlin, and completed his postdoctoral training at Temple University. He has been consistently publishing in high-impact journals, demonstrating sustained research activity in neurovirology and gene therapy. His work is conducted within collaborative teams at Temple's Center for Neurovirology, where interdisciplinary efforts aim to translate gene editing technologies into clinical applications for neurological disorders caused by viral infections.
